フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013). Shareholders approve the 2014...
RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET...
PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME...
RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014. SALES +6.3%, OPERATING INCOME +18.8% AND NET INCOME +18.1%. Consolidated...
MILANO, Italy, July 3, 2014 (GLOBE NEWSWIRE) -- Recordati announces that the U.S. Food and Drug Administration (FDA) has granted approval of...
MILANO, Italy, May 26, 2014 (GLOBE NEWSWIRE) -- Recordati announces, following its previous releases dated 24 July 2013 and 31 October 2013, the...
Consolidated revenue € 260.4 million, +6.5%. EBITDA(1) € 71.4 million, +16.4% Operating income € 62.2 million...
Shareholders approve the 2013 results: Consolidated revenue € 941.6 million, +13.7%, operating income € 195.4 million, +17.0...
MILANO, Italy, March 6, 2014 (GLOBE NEWSWIRE) -- RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS. REVENUE € 941.6 MILLION (+13.7...
LA DEFENSE, France, Feb. 26, 2014 (GLOBE NEWSWIRE) -- EURORDIS (European Organisation for Rare Diseases) announced yesterday that Orphan Europe...
A PRODUCTIVE YEAR FOR INVESTMENTS. Consolidated revenue € 941.6 million, + 13.7%. EBITDA(1) € 230.1 million...
MILAN, Italy, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Recordati announces the signature of an exclusive license agreement with Apricus Biosciences...
MILANO, Italy, Jan. 16, 2014 (GLOBE NEWSWIRE) -- Milan, 16 January 2014 - Recordati announces the approval by the Board of Directors of its 2014...
MILANO, Italy, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Milan, 31 October 2013 - Recordati announces the successful conclusion of the acquisition of...
MILANO, Italy, Oct. 30, 2013 (GLOBE NEWSWIRE) -- * Consolidated revenue € 702.0 million, + 13.2%. * EBITDA((1)) € 174.0...
Support
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
サインアップして広告なしのエクスペリエンスを体験してください
今すぐ試してください
広告を残す